After radical prostatectomy, PSA should fall to an undetectable level because the prostate—the main source of PSA—has been removed. Current European guidance expects PSA to be undetectable by about two months after surgery. A PSA that never becomes undetectable is called persistent PSA, while a PSA that first becomes undetectable and later rises is a different pattern usually described as biochemical recurrence.
01. What Should PSA Be After Radical Prostatectomy?
Why should PSA become undetectable?
Radical prostatectomy removes the prostate gland and usually the seminal vesicles as treatment for prostate cancer.
Because prostate tissue is the main source of circulating PSA, serum PSA should fall dramatically after the gland is removed.
Current EAU follow-up guidance states that PSA is expected to be undetectable approximately two months after radical prostatectomy.
“Undetectable” does not mean that every laboratory reports the same numerical cutoff.
Different assays have different lower limits of detection.
How quickly should PSA fall after surgery?
PSA does not become undetectable immediately after the operation.
PSA already circulating in the bloodstream must first clear.
For routine clinical interpretation, current EAU guidance expects PSA to be undetectable by approximately two months after radical prostatectomy.
Testing extremely early can create confusion because residual circulating PSA may still be measurable.
Is 0.01 ng/mL an abnormal PSA after prostatectomy?
Not necessarily.
Modern ultrasensitive assays can detect PSA at extremely low concentrations, including values below 0.1 ng/mL.
The clinical meaning of a single very low detectable value can be uncertain.
AUA/ASTRO/SUO guidance does not recommend ultrasensitive PSA routinely over standard PSA for every patient after primary treatment.
It may be useful in selected high-risk patients in whom very early salvage treatment would be considered.
02. What Does Detectable or Persistent PSA After Prostatectomy Mean?
What is persistent PSA?
Persistent PSA means PSA never reaches the expected undetectable postoperative level.
Current EAU evidence commonly defines PSA persistence as:
EAU data suggest persistent PSA occurs in approximately 5–20% of men after radical prostatectomy.
However, testing too early can overestimate persistence.
Current EAU evidence notes that among men tested within three weeks of surgery, many initially had PSA above 0.1 ng/mL, but a large proportion became undetectable on later testing.
This is one reason postoperative timing matters.
What can cause persistent PSA?
A PSA that remains detectable after radical prostatectomy may reflect:
- residual prostate cancer in the prostate bed;
- cancer in pelvic lymph nodes;
- previously unrecognized metastatic disease;
- or, less commonly, residual benign prostate tissue.
The PSA number alone cannot identify which explanation applies.
Pathological Grade Group, stage, surgical margins, lymph-node findings, PSA trend and imaging all contribute to interpretation.
Does persistent PSA always mean metastatic cancer?
No.
Persistent PSA is associated with a higher probability of residual or metastatic disease, but it does not prove distant metastasis.
EAU evidence shows that some men with low-level persistent PSA remain free of biochemical progression for years.
The risk is higher when persistent PSA occurs together with adverse features such as:
- high pathological Grade Group;
- seminal-vesicle invasion;
- lymph-node involvement;
- positive surgical margins;
- higher pathological stage;
- or a rapidly rising PSA.
The next step therefore depends on the entire postoperative pathology and PSA pattern.
03. What Is Biochemical Recurrence After Radical Prostatectomy?
What PSA level counts as biochemical recurrence?
Different guidelines and studies use slightly different definitions.
The most widely used U.S. definition comes from the AUA:
The EAU uses a somewhat different approach.
EAU follow-up guidance states that a confirmed rising PSA after radical prostatectomy represents PSA recurrence but also notes that no single definitive PSA threshold can be given for every post-prostatectomy relapse decision.
This difference matters because modern salvage treatment can be most effective when started while PSA is still low.
What if PSA is detectable but still below 0.2 ng/mL?
A detectable PSA below 0.2 ng/mL can have several meanings.
It may represent:
- very early recurrent disease;
- persistent residual disease;
- residual benign tissue;
- or assay-level variation when an ultrasensitive test is being used.
For patients who have not yet met the AUA BCR definition but have detectable ultrasensitive PSA, current AUA/ASTRO/SUO guidance recommends confirming a rising PSA trend before proceeding with therapy.
That prevents one very low isolated laboratory value from being treated as definitive evidence of recurrence.
Does biochemical recurrence mean the cancer has metastasized?
No.
Biochemical recurrence means PSA has returned or is rising after treatment.
It does not tell us where the prostate cancer is located.
The disease may be:
- microscopic in the prostate bed;
- in pelvic lymph nodes;
- at a distant site;
- or too small to be visible on imaging.
A measurable PSA often precedes clinically detectable recurrence by years.
How does PSA doubling time change the risk?
The speed of the PSA rise matters.
Current EAU recurrence classification after radical prostatectomy separates men into lower- and higher-risk groups using PSA doubling time and pathological Grade Group.
| EAU recurrence category after radical prostatectomy | Criteria | General implication |
|---|---|---|
| Lower-risk BCR | PSA doubling time >12 months and pathological ISUP Grade Group <4. | Recurrence often behaves more slowly; monitoring may be appropriate in selected patients. |
| Higher-risk BCR | PSA doubling time ≤12 months or pathological ISUP Grade Group 4–5. | Greater risk of progression; earlier salvage management is generally more important. |
What PSA level predicts metastasis best?
A detectable PSA and a clinically meaningful recurrence are not exactly the same concept.
Current EAU follow-up evidence notes that a postoperative PSA above approximately 0.4 ng/mL is the threshold most strongly associated with later metastatic progression.
That does not mean clinicians should wait until PSA reaches 0.4 before acting.
Salvage radiotherapy generally works better at lower PSA levels.
04. How Is PSA Monitored After Prostatectomy and What Happens If It Rises?
How often is PSA checked after radical prostatectomy?
Current EAU follow-up guidance generally recommends:
- PSA approximately every six months for the first three years;
- then approximately once per year thereafter.
The guideline also notes that evidence supporting one exact testing interval is limited.
Follow-up may be more frequent when:
- the pathology is high risk;
- PSA is detectable;
- PSA is rising;
- salvage treatment is being considered;
- or an ultrasensitive assay is being used for a specific clinical reason.
A delayed PSA recurrence can occur many years after treatment, including more than a decade later.
| Postoperative situation | Typical PSA interpretation | Usual clinical focus |
|---|---|---|
| Undetectable PSA by ~2 months | Expected postoperative response. | Continue scheduled surveillance. |
| PSA ≥0.1 at 4–8 weeks | Possible persistent PSA. | Confirm pattern and review pathology/risk. |
| Very low detectable ultrasensitive PSA | Uncertain from one result alone. | Confirm a rising trend if early salvage therapy is being considered. |
| PSA ≥0.2 with confirmation | Meets AUA biochemical-recurrence definition. | Discuss recurrence risk, imaging and salvage treatment. |
| Rapid PSA doubling time | Higher-risk recurrence pattern. | Greater urgency for multidisciplinary assessment. |
Is routine imaging needed when PSA remains undetectable?
No.
Current EAU guidance states that imaging has no routine role after curative prostate treatment when:
- PSA is not rising;
- and the patient has no symptoms suggesting recurrence.
Imaging becomes relevant when the result is likely to affect treatment planning.
When is PSMA PET/CT used after prostatectomy?
PSMA PET/CT can help determine where recurrent disease is located when PSA is persistent or rising.
Current EAU guidance recommends PSMA PET/CT in PSA recurrence after radical prostatectomy when:
- PSA is above approximately 0.2 ng/mL;
- and the result would influence subsequent treatment decisions.
A negative scan does not necessarily mean microscopic recurrence is absent, particularly when PSA is still low.
When is salvage radiotherapy considered?
Salvage radiotherapy is radiation delivered after prostatectomy when persistent or recurrent disease is suspected in the prostate bed or pelvis.
An important principle is that salvage radiotherapy works better when PSA is still low.
Current AUA/ASTRO/SUO guidance states:
- when salvage radiotherapy is being considered, it should generally be delivered while PSA is ≤0.5 ng/mL;
- in men at high risk of clinical progression, salvage radiotherapy may be offered while PSA is still below 0.2 ng/mL.
Current EAU guidance similarly emphasizes early salvage treatment and advises against waiting for a higher PSA threshold once the decision for salvage radiotherapy has been made.
Does every PSA recurrence require immediate treatment?
No.
Some biochemical recurrences progress slowly.
Current EAU guidance allows monitoring in selected men with lower-risk biochemical recurrence, particularly when:
- PSA doubling time is longer than one year;
- pathological Grade Group is below 4;
- life expectancy and comorbidities favor observation;
- and there is no other high-risk evidence.
Other men have a faster PSA rise or adverse pathology and may benefit from earlier salvage treatment.
This is why the PSA number is only one part of postoperative decision-making.
PSA After Prostatectomy at a Glance
| Question | Practical answer |
|---|---|
| What should PSA be after radical prostatectomy? | Undetectable according to the laboratory assay. |
| When should PSA become undetectable? | Current EAU guidance expects an undetectable PSA by about two months after surgery. |
| Why does PSA fall? | The prostate—the principal source of PSA—has been removed. |
| Is this also true after simple prostatectomy for BPH? | No. Simple prostatectomy leaves substantial prostate tissue, so PSA remains detectable. |
| What is persistent PSA? | Commonly PSA ≥0.1 ng/mL approximately four to eight weeks after radical prostatectomy. |
| How common is persistent PSA? | EAU evidence reports approximately 5–20%. |
| Does persistent PSA always mean metastasis? | No. |
| What can persistent PSA represent? | Residual local cancer, nodal disease, occult metastatic disease or occasionally residual benign tissue. |
| What is biochemical recurrence? | A postoperative PSA recurrence after an initial treatment response. |
| What is the AUA BCR definition? | PSA ≥0.2 ng/mL followed by a confirmatory PSA above 0.2 ng/mL. |
| Does the EAU use one universal threshold? | No. EAU guidance emphasizes confirmed rising PSA and clinical risk and states that no single threshold fits every relapse decision. |
| Does PSA 0.05 mean recurrence? | Not from one result alone. With ultrasensitive PSA, the trend should be confirmed. |
| Are ultrasensitive PSA tests routinely required? | No. Their routine use remains controversial, although they can help selected high-risk patients. |
| Does biochemical recurrence mean metastatic cancer? | No. |
| What makes recurrence higher risk? | Short PSA doubling time and adverse pathological features are major factors. |
| How often is PSA usually checked? | Approximately every six months for three years and yearly thereafter under current EAU follow-up guidance. |
| Is routine imaging needed with undetectable PSA? | No, not in an asymptomatic patient. |
| When may PSMA PET/CT be used? | EAU recommends it for PSA recurrence above approximately 0.2 ng/mL when the result will influence treatment. |
| When should salvage radiotherapy be given? | When indicated, earlier and at lower PSA levels generally provides better outcomes. |
| Does everyone with BCR need immediate treatment? | No. Selected lower-risk patients may be monitored. |
Summary
- After radical prostatectomy, PSA should fall to an undetectable level.
- Current EAU guidance expects PSA to be undetectable approximately two months after surgery.
- The exact numerical meaning of “undetectable” depends on the laboratory assay.
- Radical prostatectomy differs from simple prostatectomy for BPH; PSA remains detectable after simple prostatectomy because prostate tissue remains.
- Persistent PSA means PSA never reaches the expected undetectable postoperative level.
- EAU evidence commonly defines persistent PSA as ≥0.1 ng/mL approximately four to eight weeks after surgery.
- Persistent PSA is reported in approximately 5–20% of men after radical prostatectomy.
- Testing very early can falsely classify some men as having persistent PSA.
- Persistent PSA can reflect residual local disease, nodal disease, occult metastatic disease or occasionally residual benign prostate tissue.
- Persistent PSA does not automatically prove metastatic prostate cancer.
- Delayed biochemical recurrence is a different pattern in which PSA first becomes undetectable and later rises.
- The AUA defines post-prostatectomy biochemical recurrence as PSA ≥0.2 ng/mL with a confirmatory value above 0.2 ng/mL.
- The EAU does not recommend one universal PSA threshold for every post-prostatectomy relapse decision.
- A very low detectable ultrasensitive PSA should usually be interpreted as a trend rather than from one isolated value.
- AUA guidance recommends confirming a rising trend when PSA remains below the conventional 0.2 ng/mL BCR threshold.
- Ultrasensitive PSA assays are not routinely required for every patient.
- Biochemical recurrence does not automatically mean the cancer is metastatic.
- PSA doubling time helps distinguish lower-risk from higher-risk recurrence.
- EAU high-risk BCR after prostatectomy includes PSA doubling time ≤12 months or pathological Grade Group 4–5.
- EAU follow-up generally uses PSA every six months for three years and yearly thereafter.
- Imaging is not routinely required while PSA remains undetectable and the patient is asymptomatic.
- PSMA PET/CT can help localize recurrent disease when PSA is rising and the result will change treatment.
- Current EAU guidance recommends PSMA PET/CT for PSA recurrence above approximately 0.2 ng/mL when clinically useful.
- Salvage radiotherapy works better when delivered at lower PSA levels.
- AUA/ASTRO/SUO guidance recommends providing salvage radiation while PSA is ≤0.5 ng/mL when it is indicated.
- Selected high-risk men may be offered salvage radiotherapy at PSA below 0.2 ng/mL.
- A rising PSA should therefore be reviewed early rather than waiting for the number to become high.
Educational disclaimer: This article provides general medical education about PSA monitoring after radical prostatectomy for prostate cancer. A detectable postoperative PSA does not by itself determine whether recurrent disease is local, nodal or metastatic, and one PSA value should not be used independently to choose salvage treatment. Interpretation requires the PSA trend, surgical pathology, Grade Group, stage, margin and lymph-node status, life expectancy, imaging when indicated and discussion with the treating urology or oncology team.
Explore the PSA Pathway
For the overall testing and interpretation framework, see PSA Testing and Prostate Screening.
For what PSA represents biologically, see What Is PSA?.
For PSA changes caused by prostate tissue sampling before surgery, see PSA After Prostate Biopsy.
For interpretation of a rising PSA over time, see What Is PSA Velocity?.
For postoperative recurrence risk based on the speed of PSA growth, see What Is PSA Doubling Time?.
The next guide explains when PSA screening is usually discussed, how age changes screening decisions and why there is no single screening age for every man.
Evidence Sources
- European Association of Urology. Prostate Cancer Guidelines — Follow-Up After Radical Prostatectomy and PSA Monitoring.
- European Association of Urology. Prostate Cancer Guidelines — Persistent PSA, Biochemical Recurrence, PSA Doubling Time, PSMA PET and Salvage Treatment.
- American Urological Association / ASTRO / SUO. Salvage Therapy for Prostate Cancer Guideline.
- Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I — Treatment Decision-Making at Suspected Biochemical Recurrence After Radical Prostatectomy.
